Versant Venture Capital VI, L.P.'s Net Worth

$293 Million

Who is Versant Venture Capital VI, L.P.?

Versant Venture Capital VI, L.P. has an estimated net worth of $293 Million. This is based on reported shares across multiple companies, which include Graphite Bio, Inc., Repare Therapeutics Inc., Monte Rosa Therapeutics, Inc., Century Therapeutics, Inc., Oyster Point Pharma, Inc., Akero Therapeutics, Inc., Aligos Therapeutics, Inc., Tempest Therapeutics, Inc., Pandion Therapeutics, Inc., Passage BIO, Inc., and Black Diamond Therapeutics, Inc..

SEC CIK

Versant Venture Capital VI, L.P.'s CIK is 0001687880

Past Insider Trading and Trends

2020 was Versant Venture Capital VI, L.P.'s most active year for acquiring shares with 77 total transactions. Versant Venture Capital VI, L.P.'s most active month to acquire stocks was the month of May. 2020 was Versant Venture Capital VI, L.P.'s most active year for disposing of shares, totalling 191 transactions. Versant Venture Capital VI, L.P.'s most active month to dispose stocks was the month of December. 2020 saw Versant Venture Capital VI, L.P. paying a total of $29,049,984.00 for 29,230,767 shares, this is the most they've acquired in one year. In 2019 Versant Venture Capital VI, L.P. cashed out on 16,894,884 shares for a total of $20,081,962.66, their largest year based on trade value.